Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin

Annals of Allergy, Asthma and Immunology

Volumn 92, Issue 1, 2004, Pages 80-87

  Tsurikisawa, Naomi ^a,b   Taniguchi, Masami ^a   Saito, Hiroshi ^a   Himeno, Hideo ^a   Ishibashi, Akihiko ^a   Suzuki, Shunsuke ^b   Akiyama, Kazuo ^a  

^a SAGAMIHARA NATIONAL HOSPITAL   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; PREDNISOLONE; SULFONATED IMMUNOGLOBULIN;

ADULT; AGED; ARTICLE; CHURG STRAUSS SYNDROME; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART FUNCTION; HUMAN; MALE; MUSCLE STRENGTH; NEUROPATHY; PRIORITY JOURNAL; SKIN TEMPERATURE; TREATMENT OUTCOME;

EID: 1642577217     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61714-0     Document Type: Article

References (38)

1. Ramakrishna G, Midthun DE. Churg-Strauss syndrome. Ann Allergy Asthma Immunol. 2001;86:603-613.
2. Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome: a prospective study in 342 patients. Medicine. 1996;75:17-28.
3. Gayraud M, Guillevin L, le Toumelin P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum. 2001;44:666-675.
4. Hattori N, Ichimura M, Nagamatsu M, et al. Clinicopathological features of Churg-Strauss syndrome-associated neuropathy. Brain. 1999;122:427-439.
5. Sehgal M, Swanson JW, DeRemee RA, et al. Neurological manifestations of Churg-Strauss syndrome. Mayo Clin Proc. 1995;70:337-341.
6. Renaldini E, Spandrio S, Cerudelli A, et al. Cardiac involvement in Churg-Strauss syndrome: a follow-up of three cases. Eur Heart J. 1993;14:1712-1716.
7. Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome: clinical study and long-term follow-up of 96 patients. Medicine. 1999;78:26-37.
8. Imbach P, Barandun S, d'Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1:1228-1231.
9. Kleyweg RP, van der Meché FG, Meulstee J. Treatment of Guillain-Barré syndrome with high-dose gammaglobulin. Neurology. 1988;38:1639-1641.
10. Faed JM, Day B, Pollock M, et al. High-dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Neurology. 1989;39:422-425.
11. 1 antibodies: a double-blind, placebo-controlled study. Neurology. 1994;44:429-432.
12. Jayne DR, Davies MJ, Fox CJ, et al. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet. 1991;337:1137-1139.
13. Lockwood CM. New treatment strategies for systemic vasculitis: the role of intravenous immune globulin therapy. Clin Exp Immunol. 1996;104(Suppl):77-82.
14. Hamilos DL, Christensen J. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. J Allergy Clin Immunol. 1991;88:823-824.
15. Armentia A, Fernandez A, Sanchez P, et al. Asthma and vasculitis: response to intravenous immunoglobulins. Allergol Immunopathol. 1993;21:47-52.
16. Levy Y, George J, Fabbrizzi F, et al. Marked improvement of Churg-Strauss vasculitis with intravenous gammaglobulins. South Med J. 1999;92:412-414.
17. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33:1094-1100.
18. Coleiro B, Marshall SE, Denton CP, et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology. 2001;40:1038-1043.
19. De Geeter F, Franken PR, Defrise M, et al. Optimal collimator choice for sequential iodine-123 and technetium-99m imaging. Eur J Nucl Med. 1996;23:768-774.
20. Nagueh SF, Mikati I, Weilbaecher D, et al. Relation of the contractile reserve of hibernating myocardium to myocardial structure in humans. Circulation. 1999;100:490-496.
21. Hachamovitch R, Berman DS, Shaw LJ, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction. Circulation. 1997;97:535-543.
22. Nishimura RA, Abel MD, Hatle LK, et al. Assessment of diastolic function of the heart: background and current applications of Doppler echocardiography, part II: clinical studies. Mayo Clin Proc. 1989;64:181-204.
23. Schiller NB, Acquatella H, Ports TA, et al. Left ventricular volume from paired biplane two-dimensional echocardiography. Circulation. 1979;60:547-555.
24. Bochner BS. Systemic activation of basophils and eosinophils: markers and consequences. J Allergy Clin Immunol. 2000;106 (Suppl):S292-S302.
25. Landay AL, Muirhead KA. Procedural guidelines for performing immunophenotyping by flow cytometry. Clin Immunol Immunopathol. 1989;52:48-60.
26. Richter C, Schnabel A, Csemok E, et al. Treatment of antineutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol. 1995;101:2-7.
27. Wieland DM, Brown LE, Les Rogers W, et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med. 1981;22:22-31.
28. Giordano A, Calcagni ML, Rossi B, et al. Use of metaiodobenzylguanidine (MIBG) in pneumology. Q J Nucl Med. 1995;39(Suppl):49-54.
29. Slosman DO, Morel DR, Alderson PO. A new imaging approach to quantitative evaluation of pulmonary vascular endothelial metabolism. J Thorac Imaging. 1988;3:49-52.
30. 131I-metaiodobenzylguanidine uptake in the isolated rat lung: a potential marker of endothelial cell function. Eur J Nucl Med. 1988;13:543-547.
31. Jordan SC. Treatment of systemic and renal-limited vasculitic disorders with pooled human intravenous immune globulin. J Clin Immunol. 1995;15(Suppl):76S-85S.
32. Sharshar T, Kaveri S, Kazatchkine M. Mechanisms of action of intravenous immunoglobulin (IVIg) in autoimmune and neuromuscular disease. Electroencephalogr Clin Neurophysiol Suppl. 1999;50:486-492.
33. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest. 1994;94:1729-1735.
34. Nishikawa K, Morii T, Ako H, et al. In vivo expression of CD69 on lung eosinophils in eosinophilic pneumonia: CD69 as a possible activation marker for eosinophils. J Allergy Clin Immunol. 1992;90:169-174.
35. Hansel TT, Walker C. The migration of eosinophils into the sputum of asthmatics: the role of adhesion molecules. Clin Exp Allergy. 1992;22:345-356.
36. Nakamura S, Sung SJ, Bjorndahl JM, et al. Human T cell activation. IV: T cell activation and proliferation via the early activation antigen EA1. J Nucl Med. 1989;169:677-689.
37. Hartnell A, Robinson DS, Kay AB, et al. CD69 is expressed by human eosinophils activated in vivo in asthma and in vitro by cytokines. Immunology. 1993;80:281-286.
38. Tsukadaira A, Okubo Y, Kitano K, et al. Eosinophil active cytokines and surface analysis of eosinophils in Churg-Strauss syndrome. Allergy Asthma Proc. 1999;20:39-44.